# Medical Oncology Consultation

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: David Hume (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-EN012-SYN-TD
- Date: 1775-06-01
- Fictional facility: St. Posthumous Health Center
- Fictional author: Rohan Mehta, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

- Requested by: Fiona Gallacher, MD

## Reason for consultation

Iron deficiency anemia with three months of looser stools and dark rectal bleeding in a man of 64; colorectal cancer suspected. Colonoscopy and staging CT are booked. Please see him once they are done to review the stage, the order of treatment, and the probable need for adjuvant therapy. **S**

## History

Mr. Hume is seen at the request of Dr. Gallacher three weeks after presenting with looser stools, dark rectal bleeding, tiredness, and iron deficiency anemia. Colonoscopy thirteen days ago found a 4 cm ulcerated, non-obstructing mass at 28 cm in the sigmoid colon and no other lesions; the biopsy shows moderately differentiated adenocarcinoma. He still has two or three loose stools a day with some dark blood, and he tires on hills. He has no abdominal pain, obstructive symptoms, cough, or bone pain. He is independent, writes every morning, and wants plain information. **S**

## Examination

| System | Finding |
|---|---|
| General | Comfortable, pale |
| Eyes | Conjunctival pallor |
| Abdomen | Soft, non-tender; no palpable mass; liver not enlarged; no ascites |
| Lymph nodes | No supraclavicular or inguinal nodes |

BP 130/78 mmHg; pulse 88 bpm; respirations 16/min; temperature 36.7 °C; oxygen saturation 98% on room air; weight 87.2 kg; BMI 27.5 kg/m². All vital signs are synthetic.

## Data reviewed

Colonoscopy report and biopsy pathology with mismatch-repair immunohistochemistry (MLH1, PMS2, MSH2, MSH6 intact); CT of the chest, abdomen, and pelvis from eleven days ago; today's CEA 6.4 ng/mL, hemoglobin 10.3 g/dL, and normal liver tests; the presenting blood count and iron studies. CEA: 6.4 ng/mL (high); Hemoglobin: 10.3 g/dL (low); ALT: 24 U/L; AST: 21 U/L; Alkaline phosphatase: 88 U/L; Total bilirubin: 0.6 mg/dL. All results are synthetic.

## Assessment

1. **Adenocarcinoma of the sigmoid colon** (C18.7). Clinical stage T3 N1 on CT, mismatch-repair proficient, with a raised CEA. This is colon rather than rectal cancer and is not bulky or obstructing, so surgery first is standard; treatment before surgery is not needed. The final stage and the need for chemotherapy depend on the surgical pathology. **S**
2. **Indeterminate 9 mm liver lesion**. Too small to characterize on CT. A single liver metastasis would change the plan to a combined approach, so it should be clarified before the operation; a benign lesion such as a hemangioma or cyst is more probable with normal liver tests. **S**
3. **Iron deficiency anemia** (D50.0). Hemoglobin 10.3 g/dL with absent iron stores. Correcting it before surgery lowers the chance of transfusion; with surgery about two weeks away, intravenous iron is the practical route. **S**
4. **Family history**. A mother reported to have died of a similar bowel disorder, of unknown nature and age, is uncertain information. The tumor is mismatch-repair proficient, which makes Lynch syndrome improbable, but current guidance supports offering germline testing to people with colorectal cancer. **S**

## Recommendations

1. MRI of the liver with contrast before surgery to characterize the 9 mm lesion.
2. If the liver lesion is benign, proceed to laparoscopic sigmoid colectomy with lymph node dissection by the colorectal surgery team; no treatment before surgery.
3. Intravenous ferric carboxymaltose 750 mg now and again in one week, with a blood count and ferritin six to eight weeks later.
4. After surgery: for low-risk stage III disease (T1 to T3 with one to three nodes), three months of CAPOX; for high-risk stage III disease, six months; for stage II disease without high-risk features, surveillance alone.
5. Before any capecitabine, DPYD genotyping; check neuropathy at baseline and at every visit during and after oxaliplatin.
6. Genetic counseling for germline testing after surgery.
7. After treatment, surveillance by the CMID and NCCN schedule: CEA and examination every 3 to 6 months for two years, CT every 6 to 12 months for five years, and colonoscopy one year after resection.

## Strengths and supports

- Supports: a wide circle of friends who come to supper each week, and family nearby **S**

## Communication

Discussed with Dr. Gallacher by telephone today and copied to the colorectal surgery team; the patient agrees with the plan and asked for the next steps in writing, which were given. **S**

## Follow-up

Medical oncology will see him two to three weeks after surgery with the pathology to decide on adjuvant therapy, and will give any chemotherapy. Primary care continues to coordinate iron treatment, mood and distress screening, and survivorship care. **S**

## Guideline basis

- NCCN Clinical Practice Guidelines in Oncology: Colon Cancer, Version 4.2025 (2025), National Comprehensive Cancer Network
- Duration of Adjuvant Chemotherapy for Stage III Colon Cancer (IDEA collaboration). N Engl J Med 2018;378:1177-1188 (2018), New England Journal of Medicine
- AGA Clinical Practice Guidelines on the Gastrointestinal Evaluation of Iron Deficiency Anemia (2020), American Gastroenterological Association
- CMID: Clinical Monitoring Intelligence Database, colorectal cancer and anemia monographs (2026), Aether Forge
